SkoposBio
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
SkoposBio - overview
Location
Melbourne, VIC, Australia
Primary Industry
Pharmaceuticals
About
Based in Australia, SkoposBio, operates as a company that offers therapies for cancer treatment. Based in Melbourne, Australia, SkoposBio was founded in 2026. The company specializes in developing radiopharmaceutical therapies targeting cancer. In September 2026, SkoposBio raised AUD 12 mn in Seed funding from investors including Tanarra Capital, Tenmile, Tin Alley Ventures, and Yosemite Management.
The funding will support the clinical development of its radioactive molecule-based cancer treatments. SkoposBio specializes in the development of next-generation radiopharmaceutical therapies specifically targeting cancer. The company's core product offerings focus on precision radiopharmaceuticals, which leverage a theranostic strategy—integrating imaging with treatment to manage oncology cases effectively. These therapies are designed to address compelling oncology targets that have historically been unreachable with conventional drug treatments.
SkoposBio’s innovations aim to extend treatment options for patients with limited alternatives, indicating a commitment to enhancing the therapeutic landscape for cancer care. The company serves a global market, with its products primarily directed towards healthcare providers and institutions involved in oncology treatment. SkoposBio's revenue model is built around B2B transactions, typically involving partnerships with healthcare institutions and research organizations. The structure of these transactions may include collaborative agreements for research and development, as well as partnerships to bring their precision radiopharmaceuticals to market.
The company's focus on targeted and innovative solutions suggests that transactions are tailored to address the unique needs of clients in the oncology field. These collaborations may encompass both direct-to-consumer and institutional sales approaches as the company develops and scales its offerings within various geographical markets. The company plans to use the funding raised in September 2026 to support the clinical development of its radioactive molecule-based cancer treatments.
Current Investors
Tanarra Capital, Tenmile, Yosemite Management
Primary Industry
Pharmaceuticals
Sub Industries
Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.skoposbio.com/
Verticals
HealthTech
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
SkoposBio - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Seed | Completed | SkoposBio | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.